Method Article

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

6.2K views

⸱

DOI:

10.3791/55824

⸱

September 15th, 2017

 ,  ,  ,  , 
1Pharmacological Therapies Unit, Research Institute for Rare Diseases, Institute of Health Carlos III

* These authors contributed equally

In This Article

Summary

Vascular endothelium tightly controls leukocyte recruitment. Inadequate leukocyte extravasation contributes to human inflammatory diseases. Therefore, searching for novel regulatory elements of endothelial activation is necessary to design improved therapies for inflammatory disorders. Here, we describe a comprehensive methodology to characterize novel endothelial regulators that can modify leukocyte trafficking during inflammation.

Abstract

The endothelial layer is essential for maintaining homeostasis in the body by controlling many different functions. Regulation of the inflammatory response by the endothelial layer is crucial to efficiently fight against harmful inputs and aid in the recovery of damaged areas. When the endothelial cells are exposed to an inflammatory environment, such as the outer component of gram-negative bacteria membrane, lipopolysaccharide (LPS), they express soluble pro-inflammatory cytokines, such as Ccl5, Cxcl1 and Cxcl10, and trigger the activation of circulating leukocytes. In addition, the expression of adhesion molecules E-selectin, VCAM-1 and ICAM-1 on the endothelial surface enables the interaction and adhesion of the activated leukocytes to the endothelial layer, and eventually the extravasation towards the inflamed tissue. In this scenario, the endothelial function must be tightly regulated because excessive or defective activation in the leukocyte recruitment could lead to inflammatory-related disorders. Since many of these disorders do not have an effective treatment, novel strategies with a focus on the vascular layer must be investigated. We propose comprehensive assays that are useful to the search of novel endothelial regulators that modify leukocyte function. We analyze endothelial activation by using specific expression targets involved in leukocyte recruitment (such as, cytokines, chemokines, and adhesion molecules) with several techniques, including: real-time quantitative polymerase chain reaction (RT-qPCR), western-blot, flow cytometry and adhesion assays. These approaches determine endothelial function in the inflammatory context and are very useful to perform screening assays to characterize novel endothelial inflammatory regulators that are potentially valuable for designing new therapeutic strategies.

Introduction

Inflammation is a beneficial biological response against infectious agents, with the major aim to eliminate the pathogen and repair damaged tissue. Under certain conditions, such as chronic infections or autoimmune diseases, inflammation does not resolve. Instead, there is an aberrant reaction with continuous infiltration of leukocytes, resulting in a prolonged immune response that leads to tissue damage, fibrosis, loss of function, and overall, disability and in some cases death of the patient. These human disorders, cataloged as inflammatory diseases, all involve the blood vessels for the control of leukocyte extravasation1,2.

The endothelial cells play a fundamental role in the regulation of the inflammatory response by controlling leukocyte trafficking. When the endothelial layer is exposed to inflammatory mediators such as LPS, the resting endothelium activates and expresses pro-inflammatory cytokines (Cxcl10, Cxcl5, Cxcl1, etc.) and adhesion molecules (E-selectin, VCAM-1 and ICAM-1) that favor recruitment of circulating leukocytes to the infection site. The leukocytes primed by the released cytokines then mediate rolling and interaction with the endothelial layer through the correspondent adhesive counterparts: PSGL-1 to selectin, α4β1 integrin to VCAM-1, and αLβ2 integrin to ICAM-1. Finally, the leukocytes migrate across the vasculature towards the focus of inflammation3.

The essential role of the endothelium in regulating the inflammatory response has been demonstrated on mice that were genetically modified to express the LPS receptor, toll-like receptor 4 (TLR4), only on the endothelial cells. These endothelial-TLR4 animals were able to respond to an LPS-mediated inflammation and to detect the infection generated after bacteria inoculation, and consequently achieve infection resolution and survival at similar levels as the wild type mice4,5.

For the endothelium-regulated inflammatory response pathway, it has been postulated that the inhibition at some stages of the leukocyte-endothelium interaction would result in the reduction of trans-endothelial migration and a better prognosis for inflammatory-related diseases. In fact, several strategies targeting the endothelial activation and leukocyte-endothelium interaction have been designed to hinder extravasation of immune cells as a treatment for inflammatory disorders6,7.

In this report, we describe a thorough group of in vitro techniques to fully characterize the endothelial activity in response to the inflammatory stimulus LPS and its role in leukocyte activation and adhesion to the vascular layer. The endothelial cell model used in this manuscript was the mouse lung endothelial cell line (MLEC-04), as described by Hortelano et al.8. The MLEC-04 cell line has been validated in the literature to be an appropriate system to study endothelial activation9,10. Based on research interests, these approaches can be easily extrapolated to any endothelial or leukocyte systems and inflammatory profile. Once the endothelial parameters in the selected conditions are defined, the system can test novel drugs on the proposed experimentation to evaluate the vascular activation. In this inflammatory context, the endothelium cells tested with the compound of interest can be compared to the control conditions of the cells, and any resulting differences may inform the drug's prognostic outcome on development and progression of inflammation. To conclude, we propose a relevant system to characterize new drug targets to the endothelial cells, which can influence the design of novel vascular-specific therapies against inflammatory-related diseases.

Access restricted. Please log in or start a trial to view this content.

Protocol

1. Endothelial Cell Culture

  1. Tissue culture treated plates
    1. Coat 100 mm tissue culture plates with 2.5 mL gelatin solution (autoclaved, 0.1% gelatin in distilled water) for 30 min at 37 °C; this can be extrapolated to the required well format. Aspirate the gelatin solution and leave plates to air-dry in the tissue culture hood.
  2. Tissue culture conditions
    1. Cultivate the MLEC-04 cells inside a biological incubator (37 °C, 95% humidity, 5% CO2). Grow the cells in complete media of Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) supplemented with 10% Fetal Bovine Serum (FBS) and 100 units/mL penicillin and 100 µg/mL streptomycin (P/S).
    2. Count the cells by the standard Neubauer chamber method, and add the MLEC-04 cells to the 100 mm gelatin-treated plates in 10 mL complete media, at a low density of 2 - 11 x 104 cells/cm2. Split the cells 1:3 when they reach confluence.
      NOTE: Usually this occurs after two to three days in culture.
    3. Subculture the cells by washing the plates with 10 mL sterile Phosphate Buffered Saline (PBS) followed by adding 2 mL trypsin-EDTA solution (0.25% trypsin, 5 mM EDTA) and incubate for 3 min at 37 °C.
    4. Stop the trypsin-EDTA reaction and recover the suspended cells by adding 10 mL complete media. Spin down the cells (300 x g, 5 min), discard the supernatant, resuspend the cellular pellet in complete media and subculture appropriately.

2. LPS Treatment and Mediators

  1. Plate the MLEC-04 cells in complete media at sub-confluence into the following well format: 7 x 105 cells/well on 6-well plates and 2.5 x 105 cells/well on 96-well plates.
  2. Incubate the culture for 6 h in a cell incubator (37 °C, 95% humidity, 5% CO2). Switch the cells to incomplete media (DMEM-F12, P/S) and leave overnight (ON) to synchronize and to reduce the cell activity.
  3. Remove the media and test novel pharmacological compounds by incubating the endothelial cells with (or without) the drug in question (e.g. DT10) diluted in the incomplete media (30 min, 37 °C); add 1.4 mL/well for 6-well plate or 0.14 mL/well for 96-well plates).
  4. Challenge the cells by adding LPS to the incubation media (100 ng/mL, final concentration) for the period of time specified in each assay. Use PBS as a control.

3. Evaluation of Transcriptional Profile on Activated Endothelium by RT-qPCR

  1. Seed the MLEC-04 cells at sub-confluence in 6-well culture plates (7 x 105 cells/well). Incubate for 6 h (37 °C, 95% humidity, 5% CO2) and afterwards proceed to serum starvation (incubate ON).
  2. Remove the media and treat (or do not treat) the endothelial cell cultures with the drug of interest diluted in the incomplete media (incubate 30 min, 37 °C); add 1.4 mL/well for 6-well plate (30 min, 37 °C).
  3. Challenge the cells by adding 100 ng/mL LPS to the incubated media (as described in step 2.3) and incubate for 6 h. Stop the reaction by washing twice with cold PBS and keep plates at -80 °C until sample processing.
  4. RNA extraction
    1. Thaw the plates and add 1 mL/well RNA extraction buffer (38% phenol and 0.8 M guanidinium isothiocyanate; see table of materials). Leave for 30 min at room temperature (RT) under agitation and collect homogenate in 1.5 mL tubes.
    2. Add 200 µL chloroform and agitate gently for 15 s. Incubate for 3 min at RT and centrifuge (11,600 x g, 15 min, 4 °C).
    3. Transfer aqueous phase to another 1.5 mL tube. Precipitate RNA by adding 500 µL isopropanol followed by a 10 min incubation at RT and then centrifugation (11,600 x g, 4 °C).
    4. Discard the supernatant and wash the pellet with 75% ethanol by vortex agitation and then centrifugation (7,500 x g, 4 °C).
    5. Air-dry the pellet and solubilize RNA in 25 µL pure H2O by incubating for 10 min at 55 °C. Keep RNA at -80 °C until sample processing.
  5. Quantity and purity of RNA
    1. Quantify the RNA concentration by measuring the absorbance of the sample at 260 nm in a spectrophotometer (see Table of Materials).
    2. Measure at 230 nm and 280 nm to determine the RNA purity.
      NOTE: The ratio at 260/280 indicates protein or phenol contamination. A ratio close to 2 is acceptable. The ratio at 260/230 indicates EDTA, carbohydrates or phenol contaminants. Values between 2.0 - 2.2 are acceptable.
  6. Checking RNA integrity
    1. Run 2 µg of total RNA and an RNA ladder on a 1.5% denaturing agarose gel; visualize on a gel documentation system (see Table of Materials).
      NOTE: A 2:1 ratio of clear and sharp 28S and 18S rRNA bands indicates an intact RNA. Partially degraded RNA resolves as a smeared appearance.
  7. RT-qPCR
    1. Synthesize the complementary DNA (cDNA) from a single stranded RNA following the standard protocol (see Table of Materials)11.
  8. Evaluate gene expression by RT-qPCR
    1. Prepare the reaction mixture for each sample: Mix 2 µL cDNA, 7 µL fluorescent compound, 300 nM forward primer, and 300 nM reverse primer (Table 1) in a final volume of 13 µL, and add to the 96-Well Reaction Plate (see Table of Materials).
    2. Seal the plate with an optical adhesive cover, centrifuge (300 x g, 1 min) and run the reaction on a Real-Time PCR System (hot start 95 °C for 20 s followed by 40 cycles: 95 °C for 3 s and 60 °C for 30 s) (see Table of Materials).
    3. Analyze the results by relative quantitation using the comparative method 2-ΔΔCt with the housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or acidic ribosomal phosphoprotein P0 (36B4)12.

4. Assess Endothelial Activation by Flow Cytometry

  1. Treat the MLEC-04 cells following the conditions described in section 2 and evaluate the changes in the endothelial surface proteins by flow cytometry.
  2. Detach the cells after 6 h of LPS stimulation with the trypsin-EDTA method described in step 1.2.3, and wash with the incomplete media at 4 °C.
  3. Count the cells using the Neubauer chamber method and place 10 x 104 cells into u-bottom 96-well plates. Centrifuge (300 x g, 5 min) and discard supernatant by a 180° snap of the wrist from top to the bottom and quick recovery to the original position.
  4. Add 50 µL of the selected antibody diluted in the incomplete media (10 µg/mL, final concentration) to the cells and incubate (30 min, 4 °C).
  5. Wash the cells twice with the incomplete media following the procedure described in step 4.3, and incubate with 50 µL at 10 µg/mL of the corresponding secondary antibody coupled to FITC or a similar conjugate (30 min, 4 °C in a dark space).
  6. Wash the cells once with the incomplete media followed by a PBS wash. Recover the cells with 300 µL PBS using 1 mL pipette tips and place in cytometry tubes.
  7. Evaluate the samples in the flow cytometry system (see Table of Materials). Adjust the cell population by the forward and side scattering parameters. Gate the population of interest. Adjust gates based on the negative control from cells incubated with isotype control. Analyze the results as the percentage of positive cells or mean fluorescence intensity8.

5. Evaluate Endothelial Activation by Western Blot

  1. Seed the endothelium at sub-confluence in 6-well culture plates (7 x 105 cells/well) and treat with LPS as described in section 2. Analyze the inflammatory protein expression by the following western blot protocol.
  2. Stop the LPS stimulation at different time points to elucidate different aspects of the endothelial response:
    1. Ascertain the inflammatory proteins profile after 6 h of LPS stimulation.
    2. Determine the cell signaling every 15 min through a 60 min period.
  3. In both cases, stop the reaction by washing twice with cold PBS and store the samples at -80 °C until sample processing.
  4. Lyse cells and protein extraction
    1. Add 200 µL lysis buffer to each well (1% non-ionic surfactant, 10 mM Tris-HCl, 1mM EDTA, 150 mM sodium chloride, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 2.1 mM sodium orthovanadate at pH 7.6, supplemented with protease inhibitor cocktail) (see table of materials).
    2. Incubate for 15 min at 4 °C under agitation, scrape wells with a pipette tip and collect the homogenate in 1.5 mL tubes.
    3. Centrifuge the tubes at 11,600 x g at 4 °C.
    4. Store the supernatant in clean 1.5 mL tubes at -80 °C until processing.
  5. Measure the protein concentration by the bicinchoninic acid assay following the standard protocol (see table of materials)13.
  6. Resolve the 30 µg of total protein lysate for each sample by the standard technique of 0.1% sodium dodecyl sulfate, 10% polyacrylamide gel electrophoresis (SDS-PAGE)14. Run samples with 10 mM β-mercaptoethanol (reducing conditions) or without (non-reducing conditions) depending on the antibody used to detect the protein of interest.
  7. Transfer the separated proteins from the polyacrylamide gel to a polyvinylidene difluoride (PVDF) transfer membrane with 0.45 µm pore size using standard procedure.
  8. After transference, wash the membrane twice with PBS, 0.1% polysorbate-20 (PBS-T) and block unspecific binding sites by adding 20 mL 2% BSA diluted in PBS-T for detected phosphoproteins or 5% non-fat dry milk in PBS-T for total proteins, under agitation (90 min, RT).
  9. Dilute the selected antibody in 10 mL of the appropriate blocking buffer at the recommended concentration and incubate the membrane under agitation (ON, 4 °C). Alternatively, place the membrane in sealed plastic bags and used 5 mL of the diluted antibody.
  10. Next day, wash the membrane three times (excess PBS-T, 15 min, RT).
  11. Incubate the membrane under agitation (30 min, RT) with 10 mL of the correspondent secondary antibody bound to horseradish peroxidase (HRP) diluted at 1:10,000 in the appropriate blocking buffer.
  12. Wash the membrane three times under agitation (excess PBS-T, 15 min, RT).
  13. Incubate the membrane for 1 min with 0.1 mL/cm2 of the peroxidase substrate enhanced chemiluminescence (ECL). Place the drained membrane between two transparent plastic sheets, and insert it into the chemiluminescence detection system which includes a Charged-Coupled Device camera (CCD).
    1. Use the CCD camera to detect the signal and its software to record images with the accumulative program (images display accumulated signal at every 30 s exposure for a total 15 min period).
  14. Quantify the band intensity by densitometry using the ImageJ software following the protocol described in the user guide15.
    1. Open the sample in the ImageJ software and select the band of interest with rectangular selection tool.
    2. Select as the first lane and press plot lanes to obtain the profile plots.
    3. Delimit the area of the peaks with the straight-line selection.
    4. Measure the size of each band by clicking the inside of each peak.
    5. Represent the results with respect to loading protein control (β-actin, tubulin, etc.).

6. Evaluate Endothelial Factor Released from Leukocyte Activation by Adhesion Assays

  1. Obtain the endothelial conditioned media.
    1. Treat the MLEC-04 cells as indicated in section 2 and collect the culture supernatant after 24 h stimulation with LPS (100 ng/mL).
    2. Collect the conditioned media from the treated MLEC-04 cells and centrifuge (600 x g). Keep the supernatant in 0.5 mL aliquots at -80 °C until use.
  2. Leukocyte adhesion assay
    1. Coat the 96-well plates with 50 µL/well of selected extracellular matrix proteins diluted in PBS (except for collagen, which is diluted in 0.1 M acetic acid): fibronectin (1 - 10 µg/mL), laminin (1 - 10 µg/mL) and collagen type I (10 - 40 µg/mL). Leave ON at 4 °C.
    2. Discard the coated media and block unspecific binding sites on wells with 150 µL PBS, 1 % BSA heat-inactivated (1 min, 100 °C) for 90 min at RT.
    3. Wash the wells twice with PBS and add 100 µL of previously collected endothelial conditioned media (section 6.1) to the wells.
      NOTE: Plates are ready for performing the adhesion assay.
    4. Culture the mouse monocyte-macrophage cell line J774 in a biological incubator (37 °C, 95% humidity, 5% CO2) with Roswell Park Memorial Institute Medium (RPMI), 10% FBS, 1% P/S.
      NOTE: The J774 cells grow in suspension.
    5. Collect the J774 cells into a 15 mL tube and centrifuge (300 x g, 5 min). Discard the supernatant and resuspend the cellular pellet with 10 mL serum-free media. Count the cells in a Neubauer chamber. Centrifuge the cells (300 x g, 5 min), discard the supernatant and resuspend the cells in serum-free media at 15 x 104 J774 cells per 50 µL media.
    6. Add 15 x 104 J774 cells to each well in 50 µL serum-free media and incubate for 15 min at 4 °C followed by 1 h at 37 °C in the CO2 cell incubator.
    7. Wash the wells twice, gently by adding warm PBS; centrifuge (300 x g, 5 min) and discard supernatant by a 180° snap of the wrist from top to the bottom and quick recovery to the original position. Fix the attached cells by adding 100 µL/well of 4% paraformaldehyde (PFA) in PBS and incubate (10 min, RT).
    8. Discard the media gently and permeabilize the cells with 2% methanol in PBS for 2 min at RT. Discard the media gently and stain the cells by adding 50 µL/well of 0.5% crystal violet in 20% methanol for 90 s at RT.
    9. Wash the plate with abundant running water, discard the excess liquid and leave it to air-dry. Report the attached cells by digital camera coupled to a light microscope.
    10. Dilute the cell staining by adding 100 µL/well of 0.1 M sodium citrate, 50% ethanol. Measure the absorbance at 545 nm and represent the results as arbitrary units of absorbance or percentage of adhesion by considering 100% as cell adhesion reached to wells coated with higher ligand concentration

7. Test Endothelial Activation by Leukocyte-Endothelium Co-adhesion Assay

  1. Treat the MLEC-04 cells on 96-well plates as described in section 2 and incubate with LPS (6 h, 37 °C).
  2. Fluorescently label J774 cells with Carboxyfluorescein Succinimidyl Ester (CSFE).
    1. Wash the J774 cells in PBS following the procedure in 6.2.5. Count the cells by the Neubauer chamber method and resuspend at 1 x 106 cells/mL in PBS, 0.1% BSA.
    2. Incubate the cells with CFSE (5 µM, final concentration) for 20 min at 37 °C. Add 5 mL incomplete media and incubate (5 min, 4 °C).
    3. Wash once with incomplete media as explained in 6.2.5., resuspend at 15 x 104 cells/100 µL and proceed to the co-adhesion assay.
  3. After the endothelium treatment, wash the wells three times with incomplete media. Add CFSE-J774 cells (15 x 104 cells/100 µL) to each endothelial-coated well. Incubate the plate for 10 min at 4 °C followed by 60 min at 37 °C.
  4. Wash the wells gently, as described in 6.2.7., using warmed PBS and report the J774 adhesion to the endothelial layer by the following two methods:
    1. Lyse the cells in 0.1 M Tris-HCl pH 8.8, 1% SDS (100 µL/well) and measure the CFSE-J774 signal by fluorometry (excitation/emission = 492 nm/517 nm). Represent the results as arbitrary units of fluorescence intensity or percentage of adhesion with respect to positive control (signal from total cells added to each well).
    2. Fix the cells in 4% PFA and report the attachment of the CFSE-J774 cells to the endothelium by visualizing under a fluorescence microscope (excitation/emission = 492 nm/517 nm).

Access restricted. Please log in or start a trial to view this content.

Results

Evaluation of LPS-induced endothelial cell activation by RT-qPCR

The serum starved MLEC-04 cells were stimulated by 100 ng/mL of LPS for 6 h, and the endothelial gene expression was assessed using RT-qPCR by comparing the expression of activation markers to the resting condition. As shown in Figure 1A, the LPS-incubated MLEC-04 cells induced the mRNA expression of selected adhesion molecules involved i...

Access restricted. Please log in or start a trial to view this content.

Discussion

This endothelial protocol describes a stepwise technology that establishes the groundwork for exploring novel mechanisms involved in the regulation of the inflammatory response. These approaches are based on the study of the endothelial activity stimulated by LPS and evaluate the critical steps involved in leukocyte recruitment during the inflammatory response, specifically: endothelial cytokines release, endothelial adhesion molecules expression and leukocyte adhesion to the vascular layer. Once the endothelial paramete...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

This work was supported by the Ministerio de Economía y Competitividad (MINECO) and the Instituto de Salud Carlos III (ISCIII) (grant number IERPY 1149/16 to A.L.; MPY 1410/09 to S. Hortelano); by the MINECO through the Fondo de Investigación en Salud (FIS) (grants numbers PI11.0036 and PI14.0055 to S. Hortelano). S. Herranz was supported by IERPY 1149/16 from ISCIII.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
GelatinSigmaG9391
DMEM-F12LonzaBE12-719F
Fetal Bovine SerumSigmaA4503
Penicillin streptomycinLonzaDE17-602E
TrypsineLonzaBE17-160E
EDTASigmaED2SS
LPSSigmaL2880
TrizolSigmaT9424RNA extraction buffer
IsopropanolSigma33539
Ethanol absolutoPanreac1,310,861,612
Pure H2OQiagen1017979RNAse free
AgarosePronadisa8020
Stain for agarose gelsInvitrogens33102
SuperScript III First-Strand SynthInvitrogen18080051Reagents for RT-PCR
Fast SYBR Green Master MixApplied Biosystems4385610Fluorescent stain for qPCR
MicroAmp Fast Optical 96-WellApplied Biosystems4346906Plates for qPCR
U-bottom 96 well platesFalcon353072
Cytometry tubesFalcon352054
TX100Panreac212314Non-ionic surfactant
Tris-HClPanreac1,319,401,211
Sodium chlorideMerck1,064,041,000
Sodium pyrophosphateSigma221368
Sodium fluorideSigmaS7920
Sodium orthovanadatesigma13721-39-6
Protease inhibitor cocktailsigmaP8340
Pierce BCA Protein Assay KitPierce23225Reagents for bicinchoninic acid assay
β-mercaptoethanolmerck805,740
PVDF Transfer Membrane, 0.45 µmThermo Scientific88518
Tween-20Panreac1,623,121,611Polysorbate 20
PBSLonzaBE17-515Q
ECLMilliporeWBKLS0500
FibronectinSigmaF1141
LamininSigmaL2020
Collagen type ISigmac8919
Acetic acidPanreac1,310,081,611
Trypan blueSigmaT8154
ParaformaldehydeSigmaP6148
MethanolPanreac1,310,911,612
Crystal violetSigmaHT90132
Sodium citrateSigmaC7254
Ethanol 96%Panreac1,410,851,212
CFSESigma21888
RPMILonzaBE12-115F
SDSBio-Rad161-0418
Infinite M200TecanM200Multi mode microplate reader
Gel Doc 2000Bio-Rad2000Gel documentation system
StepOnePlusApplied BiosystemsStepOnePlusqPCR system
MACSQuant Analyzer 10Miltenyi BiotecAnalyzer 10Cytometry equipment
ChemiDoc MPBio-RadMPChemiluminescence detection system
NameCompanyCatalog NumberComments
Antibodies
PECAM-1BD Biosciences553370Use at 10 µg/mL
ICAM-2Biolegend1054602Use at 10 µg/mL
E-selectinBD Biosciences553749Use at 10 µg/mL
VCAM-1BD Biosciences553330Use at 10 µg/mL
ICAM-1Becton Dickinson553250Use at 10 µg/mL
anti-rat IgG-FITCJackson Immuno Research112-095-006Use at 10 µg/mL
anti armenian hamster-FITCJackson Immuno Research127-095-160Use at 10 µg/mL
Rat IgG isotyope controlInvitrogen10700Use at 10 µg/mL
Armenian hamster IgG isotype controlInvitrogenPA5-33220Use at 10 µg/mL
P-IκΒ-αCell Signaling2859Use at 10 µg/mL
β-ActinSigmaA5441Use at 10 µg/mL
P-ERKCell Signaling9101Use at 10 µg/mL
anti-mouse HRPGE HealthcareLNXA931/AEUse at 1:10,000
anti-rabbit HRPGE HealthcareLNA934V/AGUse at 1:10,000
anti-rat HRPSanta CruzSc-3823Use at 1:10,000

References

  1. Baumgart, D. C., Sandborn, W. J. Crohn's disease. Lancet. 380 (9853), 1590-1605 (2012).
  2. Skeoch, S., Bruce, I. N. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol. 11 (7), 390-400 (2015).
  3. Gerhardt, T., Ley, K. Monocyte trafficking across the vessel wall. Cardiovasc Res. 107 (3), 321-330 (2015).
  4. Andonegui, G., et al. Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal systemic Gram-negative bacterial infection. J Clin Invest. 119 (7), 1921-1930 (2009).
  5. McDonald, B., Jenne, C. N., Zhuo, L., Kimata, K., Kubes, P. Kupffer cells and activation of endothelial TLR4 coordinate neutrophil adhesion within liver sinusoids during endotoxemia. Am J Physiol Gastrointest Liver Physiol. 305 (11), G797-G806 (2013).
  6. Pober, J. S., Sessa, W. C. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 7 (10), 803-815 (2007).
  7. Chamorro, Á, Dirnagl, U., Urra, X., Planas, A. M. Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation. Lancet Neurol. 15 (8), 869-881 (2016).
  8. Hortelano, S. ILK mediates LPS-induced vascular adhesion receptor expression and subsequent leucocyte trans-endothelial migration. Cardiovasc Res. 86 (2), 283-292 (2010).
  9. Palazón, A. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 71 (3), 801-811 (2011).
  10. Jiménez-García, L. 8,9-Dehydrohispanolone-15,16-lactol diterpene prevents LPS-triggered inflammatory responses by inhibiting endothelial activation. Biochem J. 473 (14), 2061-2071 (2016).
  11. SuperScript® III First-Strand Synthesis System for RT-PCR. , Life Technologies. Available from: https://tools.thermofisher.com/content/sfs/manuals/superscriptIIIfirststrand_pps.pdf (2013).
  12. Livak, K. J., Schmittge, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25 (4), 402-408 (2001).
  13. Pierce BCA Protein Assay Kit. , Thermo Scientific. Available from: https://tools.thermofisher.com/content/sfs/manuals/MAN0011430_Pierce_BCA_Protein_Asy_UG.pdf (2017).
  14. He, F. Laemmli-SDS-PAGE. BIO-PROTOCOL. 1 (11), (2011).
  15. ImageJ User Guide. , ImageJ. Available from: https://imagej.nih.gov/ij/docs/guide/user-guide-USbooklet.pdf (2017).
  16. Hohsfield, L. A., Humpel, C. Intravenous infusion of monocytes isolated from 2-week-old mice enhances clearance of Beta-amyloid plaques in an Alzheimer mouse model. PloS One. 10 (4), e0121930(2015).
  17. Hofland, R. W., Thijsen, S. F. T., Verhagen, M. A. M. T., Schenk, Y., Bossink, A. W. J. Tuberculosis during TNF-α inhibitor therapy, despite screening. Thorax. 68 (11), 1079-1080 (2013).
  18. Ley, K., Laudanna, C., Cybulsky, M. I., Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 7 (9), 678-689 (2007).
  19. Tedgui, A., Mallat, Z. Anti-inflammatory mechanisms in the vascular wall. Circ Res. 88 (9), 877-887 (2001).
  20. Zheng, Y., Humphry, M., Maguire, J. J., Bennett, M. R., Clarke, M. C. H. Intracellular interleukin-1 receptor 2 binding prevents cleavage and activity of interleukin-1α, controlling necrosis-induced sterile inflammation. Immunity. 38 (2), 285-295 (2013).
  21. Pripp, A. H., Stanišić, M. The correlation between pro- and anti-inflammatory cytokines in chronic subdural hematoma patients assessed with factor analysis. PloS One. 9 (2), e90149(2014).
  22. Guha, M., Mackman, N. LPS induction of gene expression in human monocytes. Cell Signal. 13 (2), 85-94 (2001).
  23. Tabas, I., Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science. 339 (6116), 166-172 (2013).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

RT qPCRWestern BlotFlow CytometryAdhesion AssaysLeukocyte RecruitmentCytokine ExpressionAdhesion MoleculesLPS Stimulation

Related Articles